Pall Life Sciences exclusively announced the commercial launch of the Cadence Acoustic Separator (CAS) at Interphex 2016
The CAS applies acoustic wave separation technology in a single-use format for the clarification of cell culture bioprocess fluids, delivering cell and protein yields in a closed system without centrifugation.
Vice president and general manager of biopharmaceuticals, Pall Life Sciences, Michael Egholm, said: “We launched our continuous processing vision at the end of 2015, introducing the concept of acoustic wave separation technology as an enabling tool for customers to bridge the critical gap between the bioreactor and the downstream processing train.
“We have now brought that concept to fruition with the commercial launch of the CAS as the first in a series of product launches that enable continuous bioprocessing.
“The CAS technology is truly revolutionary, eliminating reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and creating a continuous feed stream for direct integration with our full portfolio.”
Pall Life Sciences obtained an exclusive license to acoustic wave separation technology in June 2015 from FloDesign Sonics (FDS).
The CAS works via acoustic forces that are applied across a countercurrent flow of bioprocess fluid, generating three-dimensional standing waves that trap cells at their nodes. This leads to aggregation and precipitation from suspension, thereby “trapping” the cells for simple extraction.
It is capable of clarifying many types of biologic products, including recombinant therapeutic proteins and monoclonal antibodies, regardless of the variability in particulate concentrations and cell culture density, turbidity and viability, according to Pall Life Sciences.
The CAS is on display in New York, NY at Interphex this week from April 26 to 28 in booth 2815.